SCHEMBL1750348

SCHEMBL1750348

COc1cccc(Cc2c(F)cccc2F)c1N

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
LMNA P02545 1/20 0.41
MAPK1 P28482 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
ALDH1A1 P00352 3/20 0.40
IDO1 P14902 3/20 0.40
KDM1A O60341 1/20 0.38
MAOA P21397 1/20 0.38
ATP4A P20648 1/20 0.38
ATP4B P51164 1/20 0.38
NFE2L2 Q16236 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
MPO P05164 1/20 0.38
KDM4E B2RXH2 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL108534 0.78 TDP1 (0.48) TAAR1L3MBTL1LMNAMAPK1SMN1; SMN2
SCHEMBL10510260 0.77 MPO (0.42) TAAR1L3MBTL1LMNAALDH1A1IDO1
SCHEMBL28846076 0.76 HTR1A (0.51) TAAR1SMN1; SMN2IDO1
SCHEMBL5829892 0.74 IDO1 (0.47) TAAR1L3MBTL1TDP1ALDH1A1IDO1
SCHEMBL1161154 0.74 TAAR1 (0.52) TAAR1LMNASMN1; SMN2TDP1ALDH1A1
SCHEMBL30122828 0.74 TAAR1 (0.52) TAAR1LMNASMN1; SMN2TDP1ALDH1A1
SCHEMBL3256812 0.73 ALDH1A1 (0.41) L3MBTL1LMNATDP1ALDH1A1KMT2A
SCHEMBL1353991 0.73 IDO1 (0.48) TAAR1LMNASMN1; SMN2TDP1ALDH1A1
SCHEMBL2426746 0.73 CD274 (0.49) TAAR1L3MBTL1LMNAMAPK1SMN1; SMN2
SCHEMBL17058000 0.73 IDO1 (0.46) TAAR1LMNASMN1; SMN2TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968534-B2 Sulfonamide derivatives, preparation thereof and use thereof as antagonists of orexin 2 receptors SANOFI-AVENTIS (FR) 2011-06-28 US disclosed
US-20090042851-A1 SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF AS ANTAGONISTS OF OREXIN 2 RECEPTORS SANOFI-AVENTIS (FR) 2009-02-12 US disclosed
EP-1981873-A1 SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-10-22 EP disclosed
WO-2007085718-A1 SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042851-A1 SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF AS ANTAGONISTS OF OREXIN 2 RECEPTORS HCRTR2, HCRTR1, NPY2R TAAR1 48/4885L3MBTL1 4824/4885LMNA 3840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.